Fasting Mimicking Diet® Is Awarded First-Ever Patent for Optimizing Human Healthspan
July 31 2018 - 3:37PM
Business Wire
L-Nutra is disrupting the health industry with
a method for promoting tissue regeneration, longevity, better
health
On July 10, L-Nutra, Inc. became the first company to market a
product that has been granted a patent by the United States Patent
and Trademark Office (USPTO) for optimizing human healthspan, the
length of time that a person is healthy. This follows a landmark
patent issued in 2016 for treating diabetes and multiple patents
previously issued for cancer treatment, but this is the first
patented protocol to address health and wellness prior to the onset
of disease. The patent is for the Fasting Mimicking Diet® (FMD®),
discovered and clinically tested by the laboratory of Valter Longo
and Keck Hospital at the University of Southern California (USC), a
nutrition technology that is proven to reduce markers for
age-related disease as well as promote tissue regeneration.
Fasting has always been part of human history; but recently,
humans have become accustomed to eating multiple times a day, every
day, causing a worldwide obesity epidemic. Over 70% of Americans
are overweight or obese. Carrying excess fat accelerates the aging
process and often leads to the early onset of diabetes, cancer,
cardiovascular disease, and Alzheimer’s. Water-only fasting is an
effective way to prevent obesity; however, the most effective
regimen consists of several consecutive days without food, which is
not only very difficult to comply with, but could pose health
challenges and side effects if done outside of a specialized
clinic. FMD protocols allow people to nourish their body with food
while keeping the body in “fasting mode.” The current embodiment of
the patent is ProLon®, a five-day FMD designed to minimize side
effects and hunger thus making periodic fasting easy, effective,
and safe. It is also currently being tested for positive effects
that are even superior to those of water-only fasting.
The patent distinguishes the Fasting Mimicking Diet from other
diets in its ability to promote tissue regeneration. This is
critical because the majority of diets only impact fat metabolism
(e.g. weight loss), and the fasting period of most forms of
time-restricted eating (such as intermittent fasting) are not
sufficient to yield this effect. The FMD positively stresses the
body to induce major cellular benefits such as autophagy (awarded
the 2016 Nobel Prize in Medicine) and stem cell-based regeneration.
This regeneration and reset of the body could support healthier
aging by helping maintain body weight and improving physical and
mental performance in a way that takes advantage of natural human
evolution, tradition, and cutting-edge science.
“This is a milestone achievement for public health, and L-Nutra
is proud to be the first to market a product developed, tested,
positioned, sold, and now patented for optimizing longevity and
healthspan,” says Joseph Antoun MD, CEO of L-Nutra. “L-Nutra’s
vision is to disrupt the current ‘sickcare’ model of medicine and
to advance the concept of healthy and youthful longevity.”
The Fasting Mimicking Diet is one of few nutri-technologies that
has undergone extensive scientific research and clinical trials at
major universities across the world. Last year, a landmark human
trial published in Science Translational Medicine demonstrated that
ProLon is clinically proven to reduce markers of the body’s aging
process, optimize weight, and maintain healthy levels of multiple
metabolic markers such as cholesterol, triglyceride, glucose, and
CRP (an inflammatory marker). The secret to the Fasting Mimicking
Diet relies on the body’s activation of the epigenetic, metabolic,
and cellular reprogramming to survive prolonged periods of
fasting.
“At L-Nutra, we believe that by understanding and respecting
nature, tradition, and science, we can promote remarkable self
repair and reset mechanisms in the human body, which eventually may
also be used to treat and cure disease,” adds Dr. Antoun. L-Nutra’s
plans include ongoing university studies to develop additional
types of Fasting Mimicking Diets for addressing specific conditions
such as multiple sclerosis, diabetes, cancer, and Alzheimer’s. For
more information, please visit L-Nutra.com.
About L-Nutra, Inc.
L-Nutra’s team of researchers and collaborators
are leaders in the field of nutrition related to longevity and
healthspan. L-Nutra has the exclusive rights from the University of
Southern California to market ProLon® and other FMD®s, which mimic
and enhance the effects of fasting, unleash the body’s natural
ability to rejuvenate itself, and promote healthy longevity. These
nutri-technologies are the result of decades of lab and clinical
research to demonstrate safety and efficacy. For more information,
please visit l-nutra.com and prolonfmd.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180731005885/en/
MediaCrier CommunicationsDanielle Caldwell310-274-1072
x214danielle@crierpr.com